Dairy and food processors that make lactose-free or lactose-reduced products are the core buyers of lactase, a food-grade enzyme that splits lactose into glucose and galactose. Ingredient and nutraceutical manufacturers building digestive-health supplements buy it too, as do specialty food producers that want enzymatic hydrolysis in place of physical separation. They purchase it as a liquid concentrate or as a powder or granule preparation, dosed into fresh milk or applied during fermentation and cheese-making.
Lactase Market Size and Outlook to 2034
The global lactase market was valued at USD 275 million in 2025. It is projected to grow from USD 294 million in 2026 to USD 497.8 million by 2034, a compound annual growth rate of 6.8% over the forecast period. Contrive Datum Insights presents these figures in its report "Lactase Market Size, Share & Industry Analysis, By Type, Application, Form, Source, End-use product, and Regional Forecast, 2026-2034".
Spending sits mostly with established formats. Neutral Lactase, the form added directly to fresh milk and dairy beverages, accounts for 61.85% of 2025 revenue, or USD 170.1 million. Acid Lactase, built for whey, cheese and other lower-pH streams, is smaller but grows at 7.95%, the fastest of any type line. By application, the Food Industry took 68% of 2025 revenue at USD 187 million, while the Pharmaceutical Industry grows faster at 8.67%. Liquid preparations led by form with 57.02% of revenue and USD 156.8 million; Powder/Granules grows at 7.89%.
Buyers also differ in where their enzyme comes from and what it goes into. Kluyveromyces lactis, the yeast-derived source, led in 2025 with 55.02% of revenue at USD 151.3 million, and Other Microbial Sources grows fastest among sources at 8.28%. Among end-use products, Milk & Fluid Dairy is the largest at 30% of revenue, or USD 82.5 million. Lactose-Free Nutritional & Other is the quickest riser at 10.29%.
Europe is the largest region, with 31.85% of global revenue in 2025 at USD 87.6 million, and it reaches USD 139.4 million by 2034. Asia Pacific is the region gaining ground: its share moves from 24.87% in 2025 to 30% in 2034, as revenue climbs from USD 68.4 million to USD 149.3 million. Middle East and Africa is the smallest region throughout, at 7.31% of 2025 revenue and 8% by 2034. The United States is the largest single country at USD 57.8 million, 21.02% of the global total.
The growth outlook rests mainly on rising diagnosed and self-identified lactose intolerance, which the study rates as a high-impact driver. The study also sets out a range around the base case. A bull case, with lactose-free product launches and nutraceutical demand at the faster end of recent experience and enzyme pricing holding steady, reaches USD 564.6 million in 2034. A bear case, with slower product expansion, membrane filtration displacing enzymes in large dairy plants and processors pressing on price, holds revenue to USD 434.4 million.
The study reports revenue and a growth rate for every line in every year from 2020 to 2034, with country-level detail for all five regions, the competitive landscape and the research methodology. It is delivered as a PDF; request a free sample to review it.